Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30595% above fair value
$228.44+7.61 (+3.45%)
Close on Nov 3, 2026Market cap $91.20BP/E –Yield –
Moderna Finance lease right-of-use assets, gross by Year
Finance lease right-of-use assets, gross ($M) ($M)
Moderna Finance lease right-of-use assets, gross: $132M in FY2025, unchanged from a year earlier.
Latest, FY2025
132
Period ended Dec 31, 2025
Change on a year earlier
0.0%
132 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 8 (Balance Sheet Details).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finance lease right-of-use assets, gross ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 132 | 0.0% | Form 10-Q (filed 2026-07-31) ↗ |
| FY2024 | Dec 31, 2024 | 132 | -75.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 529 | -66.5% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 1,581 | +84.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 857 | +1,430.4% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 56 | +471.4% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 9.80 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Finance lease right-of-use assets, gross ($M), annual FY2019–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ppe-gross-fin-rou
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?